CTI BioPharma Income Statement

Financials in millions CAD. Fiscal year is April - March.

Millions CAD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	2.01	1.39	2.94	3.39	0.33
Operating Expenses	14.14	1.39	2.94	3.39	0.33
Operating Income	-14.14	-1.39	-2.94	-3.39	-0.33
Interest Expense	-0.15	-	-	-	-
Currency Exchange Gain (Loss)	-0.03	-0	-0	-0	-
Other Non Operating Income (Expenses)	0.09	-0.17	-0.08	-0.03	-0.03
EBT Excluding Unusual Items	-14.23	-1.57	-3.02	-3.42	-0.36
Gain (Loss) on Sale of Assets	-0.66	-	-	-	-
Asset Writedown	-	-	-0.25	-	-
Pretax Income	-14.89	-1.57	-3.27	-3.42	-0.36
Net Income	-14.89	-1.57	-3.27	-3.42	-0.36
Net Income to Common	-14.89	-1.57	-3.27	-3.42	-0.36
Shares Outstanding (Basic)	125	79	60	60	-
Shares Outstanding (Diluted)	125	79	60	60	-
Shares Change (YoY)	59.05%	30.32%	0.70%	-	-
EPS (Basic)	-0.12	-0.02	-0.05	-0.06	-
EPS (Diluted)	-0.12	-0.02	-0.06	-0.06	-
Free Cash Flow	-4.71	-2.13	-5.36	-5.97	-1.27
Free Cash Flow Per Share	-0.04	-0.03	-0.09	-0.10	-
EBITDA	-2.01	-	-	-	-0.3
D&A For EBITDA	12.13	-	-	-	0.02
EBIT	-14.14	-1.39	-2.94	-3.39	-0.33
Advertising Expenses	0.02	0.02	-	0.52	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.